Kornimate/medical-research-clean huggingface dataset:
error enhancement of the velocity component

Conditions: Stroke; Hemiparesis

Summary: the purpose of this pilot study was to explore the impact of enhancement of the velocity component error in the course of reaching movements of the impaired/hemiparetic limb in an acute stroke subject. we hypothesized that the method would shift velocity profiles toward the optimal, resulting in a reduction in error. a prototype robot. this robotic device system has a two-dimensional motor, basic measurement capacities, and a robotic arm which is engaged to the subject's upper-limb in a sitting position. the enhancement of the velocity component error would shift velocity profiles toward the optimal, resulting in a reduction in error.

the wrist of the subject is connected to the robotic arm by a strip which supports the arm but allows free movements of the wrist. this configuration allows subjects with impaired grasping ability to use the system. a bio-feedback system enables the subject to perform various functional motor tasks that are presented on the screen in front of him. the system's sensors detect motor errors or deviations from an optimal/proper movement trajectory or velocity profile. any deviation in direction, velocity, acceleration or necessary force from the optimal trajectory results in applied robotic forces that enhance such errors/deviations. the sensors and the applied forces all work and compute in real time, so that the force measurements and the applied force are updated to the executed movement.

Eligibility criteria:
inclusion criteria: * single stroke * two to three weeks post stroke * able to understand simple commands * able to perform some reaching movements with the affected arm. * no other neurological, neuromuscular, orthopedic disorders and visual deficit exclusion criteria: * perceptual, apraxic, or major cognitive deficits, * shoulder joint subluxation or pain in the upper-limb, and * spasticity \> 1 (single muscle modified ashworth scale).

Keywords: cva, rehabilitation
prenatal listening to songs composed for pregnancy and symptoms of anxiety and depression: a pilot study

Conditions: Prenatal Anxiety; Depression

Summary: prenatal anxiety and depression are distressing for the expectant mother and can have adverse effects on her fetus and child. this study aimed to determine whether listening to specially composed songs would be an effective intervention for reducing symptoms of prenatal anxiety and depression over a period of 12 weeks.

prenatal anxiety and depression has negative implications for both the mother and the developing child, including developmental disorders, low birth weight, and altered immune function. it is therefore very important both to detect and to help ameliorate symptoms of anxiety and depression in pregnant women. many women do not want pharmacological interventions at this time, and with less severe symptoms it may not be appropriate. thus there is a need to find non-pharmacological methods of intervention. psychological therapies such as cognitive behavioural therapy or interpersonal therapy can be effective. but these are often not available for the large numbers of women who could benefit. though there has been evidence that music has the ability reduce anxiety, no study has quantitatively measured prenatal anxiety and depression over a long period of time. proof of efficacy could justify investment into music as an inexpensive, and non-stigmatizing method to reduce prenatal anxiety and depression and therefore benefit both the mother and child.

Eligibility criteria:
inclusion criteria: * english speaking women * at least 18 years of age.
randomized phase 2 study of 3 therapeutic modalities in ps 2/3 patients with nsclc stage iiib/iv

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: patients presenting a deterioration of the general state (performance status \[ps\] 2-3), constitute a population which needs an adapted treatment. an analysis was made of the evolution of ps 2 patients included in the eastern cooperative oncology group (ecog) 1594 trial which evaluated associations of new cytotoxic agents (gemcitabine, paclitaxel, docetaxel) with cisplatin. during this trial, the inclusion of these patients stopped due to the occurrence of toxicities more frequent than in the other populations (ps 0-1). at the end of this study, with the analysis of total toxicity, this one was not higher than that noted in the groups of ps 0 and 1 patients. in the population of ps 2 patients, 5 deaths had been noted, but the analysis showed that only 2 were due to the treatment. it was noted that the lower survival compared to the others was related to the disease and not to the treatment. these patients are often symptomatic and need palliative treatment. the benefit of chemotherapy should not be denied. they should profit from a monochemotherapy with the new cytotoxic agents, without associated platinum salt.

arm a iressa 250 mg daily prog/tox --\> taxotere 75 mg/m² d1 (d1=d22) arm b gemzar 1250 mg/m² d1 \& d8 (d1=d22) prog/tox --\> iressa 250 mg daily arm c taxotere 75 mg/m² d1 (d1=d22) prog/tox --\> iressa 250 mg daily

Eligibility criteria:
inclusion criteria: * stage iiib/iv nsclc * patients with performance status 2 or 3.

Keywords: stage iiib/iv nsclc patients with performance status 2 or 3.
an early enteral nutrition protocol in shanghai

Conditions: Critical Illness; Enteral Feeding Intolerance

Summary: compare different enteral nutrition strategy in patients with mechanical ventilation

there has been many evidence that deficiency in energy and protein take-in are associated with poor outcome in critical patients. to reach an adequate amount of energy and protein is critical in patients with respiratory failure and with mechanical ventilation, as it prevents muscle dystrophy and thus prevents icu acquired weakness, leading to a better outcome in the end. enteral nutrition is preferred as it prevents gut dysfunction in respiratory failure patients, and may prevent further infection. but there are many challenge in implement a good enteral nutrition therapy, and energy or protein deficiency is common in patient with respiratory failure. there have been many protocols aiming at reaching enough enteral nutrition for icu patients, most of which are based on a background of western and developed countries. the investigators developped a enteral nutrition protocol based on an unique cultural background of eastern developing country, trying to help the icu patients reaching nutrition target, so that the patients may have better outcome.

Eligibility criteria:
inclusion criteria: * icu patients * receiving mechanical ventilation (mv) both non-invasive ventilation and invasive ventilation * expecting mv more than 72 hours exclusion criteria: * pregnancy * icu stay \< 72hr

Keywords: feeding protocol
construction and external validation of a predictive clinico-biological score of the risk of venous thrombosis in women under combined oral contraceptives

Conditions: Venous Thromboembolism

Summary: the investigators hypothesize that some of these polymorphisms contribute to vte risk in women using coc, and that their screening could to help assess individual risk of vte before coc prescription. in order to test this hypothesis the investigators propose to build a predictive score for vte in women using coc based on clinical and biological factors. to this end the investigators have a large case study (including 766 patients) recruited at the "centre d'exploration des pathologies hémorragiques et thrombotiques" (ceht) of the laboratory of hematology (la timone hospital, marseille) between 2003 and 2013. the cases had a personal history of documented vte while using coc (pilgrim study). a great number of clinical and biological relevant phenotypes in the field of vte have already been collected (including 14 polymorphisms selected on the basis of their biological plausibility and the existence association studies).to our knowledge it is the largest study specifically conducted in order to assess genetic factors associated with vte in women using coc. these 766 cases will be compared to 766 controls from the general population (cohort nutrinet-santé). then, the predictive values of the score will be assessed in an independent multicentric validation study that the investigators will set up in the field of this project. our study should allow a better understanding of the genetic and environmental factors involved in vte related to coc use. besides, this project aims to respond to a major public health issue giving an effective tool for the decision of prescribing coc.


Eligibility criteria:
inclusion criteria: * women who had an episode of documented vte (deep vein thrombosis and / or pulmonary embolism) under coc who consulted in a specialized counseling center. * women of age. * subject agreeing to participate in this research, having signed informed consent. exclusion criteria: * absence of coc, * no knowledge of the coc generation used by the patient, * undocumented mtev episode * absence of available sample (dna), * refusal to participate in the study
artificial intelligence in anoca

Conditions: Angina, Stable

Summary: angina pectoris is diagnosed in \>180.000 people in the netherlands each year. diagnosis in angina pectoris focuses on epicardial coronary stenosis, the identification of which may lead to guideline-directed medical therapy or revascularization. however, no such stenosis is identified in 40-70% of patients. this condition, angina with no obstructed coronary artery (anoca), is more prevalent in women and is related to poor quality of life, high medical expenses, and a higher incidence of adverse events. the origin of anoca can be evaluated during invasive coronary angiography by coronary function testing (cft) to identify coronary vasomotor disorders. this relates to vasospasm of the coronary artery and microcirculation, or to impaired microvascular vasodilation. for the diagnosis of vasospasm, cft needs to result in electrocardiographic signs of myocardial ischemia as part of the diagnostic criteria. this is a critical point in the diagnosis of vasospasm, as these signs can be subtle and can vary, and are therefore prone to misinterpretation. apart from this caveat, the diagnosis approach therefore currently requires an invasive procedure for the diagnosis. this limits the broad application and hampers early identification and treatment of anoca. during cft, a coronary guide wire is routinely advanced in the coronary artery which also allows obtaining an intracoronary ecg by attaching a sterile alligator clamp to a standard electrocardiogram lead. this allows continuous recording of intracoronary ecg throughout cft on the same monitor as the routine ecg. this technique can increase sensitivity for myocardial ischemia during cft. further, holter ecg monitoring allows the identification of ischemic changes in the ecg in the outpatient setting. evidence is lacking on the patterns of myocardial ischemia that occur during spontaneous angina pectoris symptoms in anoca patients, and on the sensitivity of holter ecg for this purpose. finally, the interpretation of ischemic patterns on ecg tracings can be cumbersome, especially when changes are subtle or change from beat to beat. the use of deep learning techniques allows to automate the interpretation of ecg traces and may improve the standardized diagnosis in anoca.


Eligibility criteria:
inclusion criteria: 1. clinical indication for comprehensive coronary function testing because of persisting chest discomfort at least 2 times per week despite current medical therapy. 2. absence of obstructive coronary artery disease with an indication for revascularization, documented by means of recent coronary computed tomography angiography (ccta) or invasive coronary angiography (with invasive coronary pressure measurements if clinically indicated). 3. patient is willing and able to provide written informed consent. exclusion criteria: 1. absence of chest discomfort after initiation of medical therapy. 2. language barrier preventing sufficient understanding and communication in dutch.
serum lipids and glucose levels in relation to cvd outcomes in patients with ischemic heart failure

Conditions: Ischemic Heart Failure; Lipids; Fasting Plasma Glucose; Cardiovascular Outcomes; All-cause Mortality

Summary: current prospective cohort study is to evaluate the association between fasting lipid profiles (including total cholesterol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, triglycerides, apolipoprotein a, apolipoprotein b and lipoprotein(a)) and fasting plasma glucose at admission with cardiovascular disease outcomes (including fatal and non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, re-hospitalization due to heart failure, revascularization by percutaneous coronary intervention or coronary artery bypass grafting, or cardiovascular mortality) and all-cause mortality.in patients with ischemic heart failure and left ventricular ejection fraction \< 45 % evaluated by echocardiography during 12 months follow-up.


Eligibility criteria:
inclusion criteria: 1.diagnosed as coronary artery disease by coronary angiography; 2. left ventricular ejection fraction \< 45% evaluated by echocardiography during index hospitalization. - exclusion criteria: coexistent malignant diseases; stage 3 or more of chronic kidney disease; liver dysfunction with alt or ast higher than 3 times of normal limit range; do not want to participant in current study -
effectiveness study of hylan g-f 20 to preserve cartilage in osteoarthritis of the knee

Conditions: Osteoarthritis

Summary: that hylan g-f 20 may act to protect cartilage from the expected degree of degradation over a 12 month period in subjects with moderate to marked osteoarthritis of the knee

two courses of hylan g-f 20 ( synvisc) administered by intra-articular injection at 6 monthly intervals. mri examinations of the knee for estimation of cartilage volume prior to treatment, before second course and at 12 months in 40 subjects with grade 2/3 osteoarthritis of knee . a further 40 subjects with similar degree of osteoarthritis of knee who do not receive hylan g-f therapy will be assessed by mri in identical manner.

Eligibility criteria:
inclusion criteria: * grade 2 or 3 osteoarthritis knee age 18 - 80 pain score vas \>39 mm on 100mm scale exclusion criteria: * surgery in prior 12 months significant valgus deformity recent trauma use of opioid analgesia unstable medical condition recent corticosteroid injection morbid obesity

Keywords: osteoarthritis knee hylan
expanded haploidentical natural killer cells as consolidation strategy for children/young adults with aml

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical nk cells as consolidation therapy for children/young adults with intermediate risk aml.

immunotherapy with nk cells may improve the treatment results in aml. for better efficiency high cell doses or several infusions of nk cells are required. for this purpose, donor nk cells are expanded in the presence of feeder k562-mbil21-41bbl cell line. the cycle of immunotherapy includes chemotherapy (cyclophosphamide, fludarabine) followed by two doses of nk cells infusion.

Eligibility criteria:
inclusion criteria: patients: * primary intermediate risk aml in molecular complete remission; * primary high risk aml in molecular complete remission awaiting unrelated hsct; * karnofsky or lansky performance scale greater or equal to 70; * written informed consent. donors: * haploidentical family donor; * donor suitable for cell donation and apheresis according to standard criteria; * written informed consent. exclusion criteria: patients: * uncontrolled infection; * severe hepatic dysfunction: sgot or scpt \>=5x upper limit of normal for age; * positive serology for human immunodeficiency virus (hiv). donors: * pregnancy; * positive serology for hiv, hepatitis b or c.

Keywords: natural killer cells immunotherapy
evaluation of post operative pain after using two different types of sealers

Conditions: Post Operative Pain

Summary: conventional endodontic treatment is done using two different types of sealers in the obturation to evaluate the post operative pain between the two sealers

study will be performed on patients diagnosed with symptomatic irreversabe pulpitis. treatment protocol for all patients is conventional root canal treatment access cavity and cleaning and shaping procedures will be executed for all patients with the same protocol selected patients will then be divided into two groups, group1: all canals will be obturated using resin standard sealers. group2: all canals will be obturated using high flow bioceramic sealers that accept warm vertical compaction post operative pain in the two groups will be evaluated using the visual analoug scale and compared at different time periods (12h, 24h, 48h, 72h)

Eligibility criteria:
inclusion criteria: * • patients age ranges from 18-50 years old. * patients with teeth diagnosed with symptomatic irreversible pulpitis. * normal periapical condition confirmed by normal periapical radiograph or that with minimal widening of the pdl space * the teeth are restorable * teeth are periodontally free. exclusion criteria: * • teeth with immature roots * non restorable teeth * medically compromised patients with systemic complication that would alter the treatment. * necrotic teeth * teeth with apical periodontitis or periapical lesions * teeth that need multiple visits treatment
first evaluation of the moda-flx hemodialysis system™ in real world clinical settings

Conditions: End Stage Renal Disease; End Stage Renal Disease on Dialysis; End Stage Kidney Disease

Summary: this is a non-significant risk study utilizing a device cleared for use by the fda under its 510(k) clearance. consented patients will complete their usual dialysis treatment under professional care in an ichd (in-center hemodialysis) setting.


Eligibility criteria:
inclusion criteria: * have a diagnosis of end stage kidney disease (eskd) adequately treated by maintenance dialysis (defined as achieving a spkt/v ≥ 1.2 or stdkt/v ≥ 2.1) and be deemed stable by their treating nephrologist prior to consent. * must sign the informed consent and a health insurance portability and accountability act of 1996 (hipaa) compliant authorization statement. * understand the nature of the procedures and the requirements of the study. exclusion criteria: * have a significant cognitive impairment that would preclude informed consent or the capacity for completing dialysis as prescribed by their treating nephrologist. * in the opinion of the treating nephrologist, any other reason in which study participation would result in undue risk, including but not limited to protocol required prescription parameters. * are contraindicated for or not indicated to use the moda-flx hemodialysis system™ according to the instructions for use (ifu).
cancer anorexia and the central nervous system

Conditions: Cancer Cachexia

Summary: the pathogenesis of cancer anorexia is complex and multifactorial. however, a number of consistent and robust evidence point to a prominent role for the central nervous system. in particular, the hyperactivation of the immune system, due to tumour growth, causes a systemic inflammatory response primarily mediated by pro-inflammatory cytokines. at the central level, inflammatory response profoundly alters the activity of the hypothalamic nuclei, which are involved in the regulation of energy homeostasis. in particular, pro-inflammatory cytokines inhibit prophagic neurons activity, while enhance the activation of the anorexigenic neurons. although supported by compelling experimental evidence, it should be acknowledged that this pathogenic hypothesis has not been confirmed yet by human studies. aim of the present study is to determine the specific pattern(s) of the brain activation after assumption of a standard meal in both anorexic and non-anorexic cancer patients to reveal potential differences, which will be correlated with the levels of concurrently measured circulating pro-inflammatory cytokines. the results obtained would help in assessing the role of the central nervous system and, in particular of the hypothalamus, in the pathogenesis of cancer anorexia.

after approval of the study protocol by the ethical committee of our institution (azienda policlinico umberto i, sapienza university, rome, italy), 9 anorexic cancer patients, 4 non-anorexic cancer patients and 2 healthy individuals will be studied. the sample size is based on studies of neuroimaging already published and available on international journals. patients with confirmed cancer diagnosis will be enrolled before the initiation of any anti-cancer treatments. the presence/absence of anorexia will be investigated using a specific questionnaire (cangiano et al., 1990) and a visual analogue scale (vas). after an overnight fasting, blood samples will be collected from cancer patients and control subjects and interleukin(il)-1, il-6 and tumor necrosis factor-α (tnf-α) levels will be measured by a commercially available elisa kit. on the same day, hypothalamic activation pattern(s) will be evaluated in patients and in control subjects by fmri. after basal evaluation, all the groups will receive a standard oral meal, i.e., a 200 ml hypercaloric oral nutritional supplement providing 300 kcal, and then a second fmri scan will be performed. using a computerized software, the average value of the grey for the hypothalamus will be calculated, and normalized for the one obtained in the basal condition, to obtain the percentage (%) of activation (or inhibition) of the hypothalamus. data obtained will be statistically analyzed using the t-student and bonferroni tests.

Eligibility criteria:
inclusion criteria: * lung cancer patients at diagnosis exclusion criteria: * patients treated with immunosuppressors, with concomitant wasting diseases (e.g. aids, trauma, end-stage renal disease)

Keywords: anorexia cancer hypothalamus inflammation
microenvironment tumor effects of radiotherapy - comprehensive radiobiology assessment trial

Conditions: Locally Advanced Cervical Carcinoma; Locally Advanced Cervical Cancer; Locally Advanced Pancreas Cancer; Locally Advanced Pancreatic Carcinoma; Locally Advanced Pancreatic Cancer; Cervical Cancer; Pancreas Cancer; Pancreatic Cancer; Cancer of the Cervix; Cancer of the Pancreas

Summary: this study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.


Eligibility criteria:
inclusion criteria: * confirmation of intent to receive radiotherapy for one of the following diagnoses: * cervical cancer * pancreatic cancer * ecog performance status ≤ 2 * at least 18 years old * able to understand and willing to sign an irb-approved written informed consent document exclusion criteria: * any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician

Keywords: radiotherapy chemotherapy cervical cancer pancreatic cancer biospecimen